Cancer cost 'becoming unsustainable' in rich nations


STOCKHOLM (Reuters) - An explosion of new technologies and treatments for cancer coupled with a rapid rise in cases of the disease worldwide mean cancer care is rapidly becoming unaffordable in many developed countries, oncology experts said on Monday.

With costs ballooning, a radical shift in thinking is needed to ensure fairer access to medicines and address tricky questions like balancing extra months of life for patients against costs of a new drug, technology, or care plan, they said.

"The cancer community needs to take responsibility and not accept a substandard evidence base and an ethos of very small benefit at whatever cost," said a report commissioned by the Lancet Oncology medical journal on the costs of cancer care.

"There should be fair prices and real value from new technologies."

Some 12 million people worldwide are diagnosed with cancer each year and that number is expected to rise to 27 million by 2030.

The cost of new cancer cases is already estimated to be about $286 billion (U.S.; 212 billion euros) a year, with medical costs making up more than half the economic burden and productivity losses account for nearly a quarter, according to Economist Intelligence United data cited in the report.

The report, led by Richard Sullivan of Britain's King's Health Partners Integrated Cancer Center in London, said policymakers, doctors, patients groups, and the health industry should work together to find ways to stem future cost rises.

"We are at a crossroads for affordable cancer care, where our choices -- or refusal to make choices -- will affect the lives of millions of people," said Sullivan, who presented his report at the European Multidisciplinary Cancer Congress (EMCC) in Stockholm.

"Do we bury our heads in the sand, keep our fingers crossed, and hope that it turns out fine, or do we have difficult debates and make hard choices?"

Sullivan's team, which brought together 37 experts from wealthy countries, found that cancer costs are driven by many factors, including aging populations and rising demand for healthcare, as well as increasingly sophisticated and expensive targeted cancer drugs.

Prices for some of the latest experimental drugs unveiled at the EMCC -- including a highly sophisticated armed antibody drug from Roche and a so-called alpha-pharmaceutical from Bayer and Algeta -- are likely to reach into the tens of thousands of dollars per patient.

The Lancet report pointed to Dendreon's Provenge prostate cancer treatment -- which costs more than $100,000 (74,000 euros) for a three-dose course and was found in trials to improve survival by several months in patients with few other options.

"How should we determine its value?" the report asked.

Michael Baumann, president of the European Cancer Organization, said there was an "explosion of new possibilities" in cancer treatment and care. This was exciting for scientists, oncologists and cancer patients, he said, but also made it "absolutely necessary to think about this cost issue now."

By Kate Kelland


Lancet Oncology, September 2011.

Last Updated: 2011-09-26 11:17:18 -0400 (Reuters Health)

Copyright © 2011 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Page 1 of 1249
Next Page